As presented at WODC, ACA Pharma outlines a fast, compliant lane that starts in Macau and bridges into China’s Greater Bay Area — so teams can begin treating patients in 30–90 days while building toward broader access.
Access shouldn’t wait years when safety and efficacy are established: a Macau-first start reuses global dossiers, de-risks compliance with PV/QA guardrails, and validates demand at real sites.
In China, ~20M people live with rare diseases — most presenting in childhood — while families face 4–5 years to diagnosis and conventional entry adds more years. Early, supervised access bridges that time gap while originators advance full registrations and scale across the Greater Bay Area.
A registration-first mindset in Mainland China often stalls with in-country rules, heavy dossier admin, and local clinical trials — long before a single patient is treated. Lean teams then juggle import permits, customs, cold chain, and site-by-site onboarding while fragmented demand, pricing/reimbursement variance, FX, and compliance risks sap bandwidth. Net result: months–years lost to setup, not care; ACA Pharma’s Macau Fast-Track cuts through this while preserving safety and quality.
Macau Fast-Track: months, not years
Using your existing FDA/EMA/MHRA dossier as-is (no updates or embassy notarization; a short <10-item Macau list), we file in Macau and secure local approval in 30–90 days.
Immediately post-approval, a provincial GBA filing enables supervised cash-pay supply to 45 hospitals, with extensions for orphan/clinically urgent products to leading rare-disease departments in Beijing, Shanghai, Hainan, Tianjin, and Chongqing — and for pediatric orphan drugs, to the top 44 pediatric centers nationwide.
ACA Pharma handles end-to-end execution—registration, PV/QA, import/export, cold chain, warehousing, sales & distribution, logistics, hospital onboarding, marketing and academic promotion—so real patients start therapy in months vs years while you validate demand and build a scalable bridge into Greater China.
Group NPP Hospital Procurement
For originators who prefer to avoid registration, Group NPP activates a national network of 44 leading pediatric centers (covering ~95% of pediatric rare-disease demand). Hospitals secure site import permits; we negotiate group terms for predictable coverage. Paperwork is minimal—purchase agreement + CDA, no exclusivity, no distributor contract. PV/QA, cold chain, and traceability run on our standard platform. Typical timing from greenlight to first deliveries is ~3 months, giving families access now while you preserve full optionality for future filings.
Case snapshot: 4-year-old with DMD
A 4-year-old with Duchenne showed biomarker elevation, MRI-confirmed muscle loss, and early cardiac strain. Via Macau Fast-Track, we registered deflazacort (marketed as Emflaza in the U.S.) and imported product without local trials or NMPA approval in <62 working days; therapy began at 6 mg/day under hospital supervision with structured PV/QA.
Framed not as a costly “foreign import” but a targeted deregulation for clinically needed, otherwise unavailable pediatric medicine, the case drew national coverage — the first pediatric orphan access via this route into China — proving that with established safety/quality and disciplined execution, access happens in months, not years.
Commercial model that de-risks originators
We are the buyer: we take title ex-works at your warehouse, export from the U.S., and import via our licensed entities across Greater China and SE Asia (serving as local MAH where applicable). We run end-to-end execution — customs, warehousing, distribution, hospital onboarding, marketing/academic promotion, and sales — and collect from the supply price. You avoid fixed-asset investment and field build-out; your obligation is manufacturing COGS. Contracting is simple with a single U.S. counterparty, and we typically prepay in USD, removing FX and capital-control risk.
When this pathway fits — and when it doesn’t
Best fit: Therapies with established global safety/efficacy that fill a clear unmet need —especially pediatric orphan assets. For Greater Bay Area entry, the bar is unmet need: even non-orphan products can qualify if the indication/clinical use meaningfully differs from what’s locally available.
Poor fit: Commodities/me-toos with multiple domestic generics or no clinical step-up. These won’t fast-track and shouldn’t use this route.
The fastest compliant route into China—backed by execution
We deliver speed and certainty: Macau approval in 30–90 days, ~80% market share of all Macau approvals (including third-party registrations), and parallel Hong Kong & Singapore registrations with no local clinical trials. Because we’ve done this repeatedly, we bring pattern recognition, regulator rapport, and end-to-end execution — from registration and warehousing to distribution, marketing, and academic promotion. With 500+ field reps in every province, offices in Macau, Hong Kong, and Singapore, and SOE distributor ties, we don’t just open the door—we take you the rest of the way across China and Southeast Asia.
About ACA Pharma
ACA Pharma delivers the fastest compliant route into China: we start in Macau and scale across the Greater Bay Area and priority pediatric/rare-disease centers, while running end-to-end commercialization (registration, import/export, warehousing, distribution, hospital onboarding, promotion, and sales) across Greater China and Southeast Asia. Our 500+ field team, regulator rapport, and SOE distributor ties convert early access into durable adoption — supported by disciplined PV/QA and real-world evidence that helps de-risk national expansion.
Recent updates:
